TrianglePlixorafenib (NCT05503797)
Plixorafenib trial for Cancer Harboring BRAF Alterations (NCT05503797). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for people aged eight or older, weighing at least twenty-five kilograms, with eligible advanced solid or primary brain tumors carrying a BRAF fusion or V600E mutation. Tumor type and previous-treatment rules differ across four cohorts; pediatric V600E brain tumors must be high-grade.
The idea: oral plixorafenib blocks altered BRAF growth signaling. Researchers assess tumor response, safety, or drug exposure, depending on cohort. Treatment continues until progression, unacceptable toxicity, or another stopping reason.
This phase 2 study plans 254 patients. Fore Biotherapeutics sponsors the study; twenty-eight US sites recruit.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.